# ATAGLU: Study of Glucose Metabolism in HIV Positive Patients That Switch From Another Protease Inhibitor to Atazanavir

> **NCT02102048** · NA · UNKNOWN · sponsor: **University of Roma La Sapienza** · enrollment: 300 (estimated)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Atazanavir

## Key facts

- **NCT ID:** NCT02102048
- **Lead sponsor:** University of Roma La Sapienza
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-01
- **Primary completion:** 2014-03
- **Final completion:** 2014-07
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2014-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02102048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02102048, "ATAGLU: Study of Glucose Metabolism in HIV Positive Patients That Switch From Another Protease Inhibitor to Atazanavir". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02102048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*